Orchestra BioMed Q3 Loss Narrows to $18.8M; Cash Runway Extended to 2028
OBIO sits 66% above its 52-week low of $3.46.
Summary
Orchestra BioMed posted a Q3 net loss of $18.75M (vs $20.83M a year ago) and ended September with $101.9M in cash and securities; management now projects funding through 2028, bolstered by the $80.5M net raised in its November offering.
Key Events · Earnings and Guidance · OBIO
-
Q3 Net Loss Narrows to $18.75M
Third-quarter net loss was $18.75M versus $20.83M in Q3 2025; nine-month net loss widened to $63.2M from $58.9M.
-
Cash Runway Extended Through 2028
Company held $101.9M in cash, equivalents and marketable securities at September 30, 2026 ($27.8M cash + $74.1M securities), and projects funding through 2028.
-
R&D Spend Climbs 21% on Trial Ramp
Nine-month R&D rose to $50.1M from $41.4M, driven by BACKBEAT and Virtue trial costs; Q3 R&D was $17.7M versus $14.0M.
-
Interest Expense Jumps on New Debt
Net interest expense reached $5.1M for nine months versus $385K a year earlier, reflecting the Ligand royalty liability and Medtronic convertible note.
Analysis · OBIO · Industrial Applications And Services
The bottom line improved modestly, with Q3 net loss of $18.75M versus $20.83M a year earlier, helped by an $8.4M gain on the sale of its Vivasure stake and a $1.2M non-cash gain from remeasuring the Series A preferred derivative. Offsetting that, R&D spending climbed 21% to $50.1M for the nine months as the BACKBEAT and Virtue trials ramp, and net interest expense jumped to $5.1M from $385K as the Ligand royalty and Medtronic note began accruing. Liquidity is the key takeaway: $101.9M in cash and marketable securities at quarter-end, plus the $80.5M net raised in the November 9 offering, gives management a runway it now projects through 2028 — removing near-term financing risk while the pivotal trials read out.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OBIO was trading at $5.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $344.4M. The 52-week trading range was $3.46 to $6.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.